<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04360369</url>
  </required_header>
  <id_info>
    <org_study_id>16305-TPR-28</org_study_id>
    <nct_id>NCT04360369</nct_id>
  </id_info>
  <brief_title>Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry</brief_title>
  <official_title>Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reichert, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reichert, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine if the Tono-Vera Tonometer accurately measures intraocular pressure (IOP). The
      hypothesis of this test is to confirm the Tono-Vera Tonometer is equivalent to the Goldmann
      Applanation Tonometer (within +/- 5.0 mmHg).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Tono-Vera Tonometer (Reichert, Inc.) is a portable rebound tonometer intended to measure
      IOP. Subjects will undergo a standard ophthalmologic examination. Subjects will then be
      measured with four tonometers: Goldmann Applanation Tonometer (C.S.O. SRL), Ocular Response
      Analyzer G3 (Reichert, Inc.), iCare ic100 tonometer (iCare Finland Oy), and Tono-Vera
      Tonometer.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>All study-related tests will be conducted in a single stage, with one clinical visit, to a single clinical center.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate compliance with ANSI Z80.10-2014-Ophthalmics-Ophthalmic Instruments-Tonometers.</measure>
    <time_frame>Through study completion, approximately 4 months.</time_frame>
    <description>Subjects will be distributed into Low IOP, Medium IOP, and High IOP groups based on Goldmann Applanation Tonometer measurements. The Tono-Vera Tonometer measurements will be within +/-5.0 mmHg of the Goldmann Applanation Tonometer measurements in all groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Data collection for two measurement modes.</measure>
    <time_frame>Through study completion, approximately 4 months.</time_frame>
    <description>Tono-Vera has two measurement modes: A 6-measurement mode &amp; &quot;Quick&quot; measurement mode. The 6-measurement mode will be used during this study. It will be possible to post-process the results to determine the IOP value that would have been obtained using Quick mode. As such the sponsor will be able to ensure the accuracy of both measurement modes compared to Goldmann Tonometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Data collection for device calibration.</measure>
    <time_frame>Through study completion, approximately 4 months.</time_frame>
    <description>The study will collect data on a large number of patients over a wide range of IOP values. The sponsor may use the collected data in a post-hoc analysis to verify that the Tono-Vera Tonometer factory calibration is optimal.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Intraocular Pressure</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Goldmann Applanation Tonometer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Measurement of IOP with Goldmann Applanation Tonometer. All subjects will participate in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORA G3 and ic100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers. All subjects will participate in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tono-Vera Tonometer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measurement of IOP with Tono-Vera Tonometer. All subjects will participate in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IOP with Goldmann Applanation Tonometer</intervention_name>
    <description>Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (&gt;16 to &lt;23 mmHg), or High IOP (&gt;23 mmHg).</description>
    <arm_group_label>Goldmann Applanation Tonometer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IOP with comparator ORA G3 and ic100 tonometers</intervention_name>
    <description>Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.</description>
    <arm_group_label>ORA G3 and ic100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IOP with Tono-Vera Tonometer</intervention_name>
    <description>Measurement of IOP with Tono-Vera Tonometer</description>
    <arm_group_label>Tono-Vera Tonometer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be male or female, between the ages of 18 and 90 years old;

          -  Be able and willing to provide signed informed consent

          -  Be able to follow study instructions

        Exclusion Criteria:

          -  Subjects with only one functional eye;

          -  Subjects with one eye having poor or eccentric fixation;

          -  Subjects with central corneal thickness greater than 600 µm or less than 500 µm (about
             2 standard deviations the human mean);

          -  Subjects with corneal scarring or who have had corneal surgery, including corneal
             laser surgery;

          -  Subjects with concomitant ocular diseases such as: microphthalmos, buphthalmos,
             nystagmus, keratoconus, severe dry eye syndrome, blepharospasm, any other corneal or
             conjunctival pathology or infection;

          -  Contact lens wearers;

          -  Known allergy to proparacaine or fluorescein as these are used to anesthetize the eye
             and allow IOP measurement, respectively, when used with the GAT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Tseng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Opthalmology, Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felipe Medeiros, MD, PhD</last_name>
    <phone>(919) 684-0201</phone>
    <email>felipe.medeiros@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Cabezas</last_name>
    <phone>(919) 684-0201</phone>
    <email>eric.cabezas@duke.edu</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tonometry, Ocular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

